Kallyope Inc. is aiming to harness the potential of the gut-brain axis to develop consumer products and transformational therapeutics that improve human health and nutrition. The biotech company announced $44 million of Series A financing last week, and boasts numerous members of the national academies, two Lasker Award winners, and three Nobel laureates among its founders and scientific advisory board.